Literature DB >> 14667814

Gene structure and expression of the 5'-(CGG)(n)-3'-binding protein (CGGBP1).

Frauke Naumann1, Ralph Remus, Birgit Schmitz, Walter Doerfler.   

Abstract

The human nuclear 5'-(CGG)(n)-3'-binding protein (CGGBP1) influences the expression of the fragile X mental retardation (FMR1) gene by specifically interacting with the 5'-(CGG)(n>5)-3' repeat in its 5' untranslated region. Here, we show that CGGBP1 binds to 5'-(CGG)(n)-3' repeats with n>or=5 and to interrupted repeats. The genomic and mRNA organization of the human and murine CGGBP1 genes was studied and the human gene was mapped to chromosome 3p. Due to alternative polyadenylation, mRNAs of 1.2 and 4.5 kb are transcribed at varying ratios in human and murine cells and in embryonic, fetal, and adult tissues. The human and the murine genes, including promoters and large parts of the untranslated regions, are highly conserved. A sequence of 235 nucleotides 5' upstream of CGGBP1 is essential for promoter activity in transfection experiments. Complete in vitro methylation inactivates the promoter, which is unmethylated in human cells as shown by bisulfite genomic sequencing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14667814     DOI: 10.1016/s0888-7543(03)00212-x

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  13 in total

1.  Defining the role of the CGGBP1 protein in FMR1 gene expression.

Authors:  Martina Goracci; Stella Lanni; Giorgia Mancano; Federica Palumbo; Pietro Chiurazzi; Giovanni Neri; Elisabetta Tabolacci
Journal:  Eur J Hum Genet       Date:  2015-08-26       Impact factor: 4.246

2.  A distinct DNA-methylation boundary in the 5'- upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome.

Authors:  Anja Naumann; Norbert Hochstein; Stefanie Weber; Ellen Fanning; Walter Doerfler
Journal:  Am J Hum Genet       Date:  2009-10-22       Impact factor: 11.025

3.  The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome.

Authors:  Daman Kumari; Karen Usdin
Journal:  Hum Mol Genet       Date:  2010-09-14       Impact factor: 6.150

Review 4.  Chromatin remodeling in the noncoding repeat expansion diseases.

Authors:  Daman Kumari; Karen Usdin
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

5.  Epigenetic control of the critical region for premature ovarian failure on autosomal genes translocated to the X chromosome: a hypothesis.

Authors:  Flavio Rizzolio; Cinzia Sala; Simone Alboresi; Silvia Bione; Serena Gilli; Mara Goegan; Tiziano Pramparo; Orsetta Zuffardi; Daniela Toniolo
Journal:  Hum Genet       Date:  2007-01-31       Impact factor: 4.132

6.  CGGBP1 regulates cell cycle in cancer cells.

Authors:  Umashankar Singh; Pernilla Roswall; Lene Uhrbom; Bengt Westermark
Journal:  BMC Mol Biol       Date:  2011-07-07       Impact factor: 2.946

7.  CGGBP1 mitigates cytosine methylation at repetitive DNA sequences.

Authors:  Prasoon Agarwal; Paul Collier; Markus Hsi-Yang Fritz; Vladimir Benes; Helena Jernberg Wiklund; Bengt Westermark; Umashankar Singh
Journal:  BMC Genomics       Date:  2015-05-16       Impact factor: 3.969

8.  A DNA sequence directed mutual transcription regulation of HSF1 and NFIX involves novel heat sensitive protein interactions.

Authors:  Umashankar Singh; Erik Bongcam-Rudloff; Bengt Westermark
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

9.  eIF4E is a central node of an RNA regulon that governs cellular proliferation.

Authors:  Biljana Culjkovic; Ivan Topisirovic; Lucy Skrabanek; Melisa Ruiz-Gutierrez; Katherine L B Borden
Journal:  J Cell Biol       Date:  2006-10-30       Impact factor: 10.539

10.  CGGBP1 phosphorylation constitutes a telomere-protection signal.

Authors:  Umashankar Singh; Varun Maturi; Rhiannon E Jones; Ylva Paulsson; Duncan M Baird; Bengt Westermark
Journal:  Cell Cycle       Date:  2013-10-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.